BioArctic AB has signed a research and collaboration agreement with Eli Lilly potentially worth $1 billion, researching a new treatment combining BioArctic’s proprietary BrainTransporter technology with an undisclosed Lilly drug candidate in neurodegeneration.
See-and-Treat Concept using Radioactive Smart Probes: Professor Rudolf Werner provides an overview of established and future indications in clinical practice, highlighting advances in theranostics and their growing impact on precision oncology.
The Novo Nordisk Foundation is launching a new European incubator network to turn academic discoveries in cardiometabolic disease into drug development projects, extending the broader European innovation push it set in motion earlier this year through a DKK5.5bn (€736 million) commitment to the BioInnovation Institute (BII).
Dublin’s Jazz Pharmaceuticals has inked a cancer research collaboration potentially worth more than $4 billion plus royalties with AbCellera, the Vancouver biotech backed by billionaire investor and political activist Peter Thiel.
UK antifungal specialist F2G and Japanese partner Shionogi have announced positive topline results from the global Phase III OASIS trial of olorofim in patients with invasive aspergillosis, a life-threatening fungal infection that mainly affects immunocompromised patients.
After months of regulatory uncertainty, uniQure says the FDA will accept three-year Phase I/II data as the primary basis for an accelerated approval application for AMT-130.
Delivering therapeutic genetic material safely to the correct target in the body is one of the big challenges of modern medicine. We talked to David Del Bourgo, CEO of WhiteLab Genomics, about how AI is helping design a new generation of vectors to tackle neurological diseases.
European biotech is seeing both encouraging momentum and challenges. Innovation from European academia continues to inspire therapeutic concepts.
With a first $50 million tranche of its Series B financing and a commercial partnership with MEDICE, HMNC Brain Health has secured fresh capital for its depression programmes. The deal marks an important milestone for the Munich-based company – nearly a decade after it first set out to transform psychiatry through precision medicine.
Finnish biotech Aplagon has raised €4.8m to broaden Phase II development of its lead candidate APAC, a first-in-class antiplatelet and anticoagulant therapy for thrombo-inflammatory diseases. The financing will support a new Phase II clinical programme in arteriovenous fistula (AVF) maturation failure in patients with end-stage kidney disease.
Andre Dallavalle
WhiteLab Genomics
Kurma Partners
NIH